OncoMatch/Clinical Trials/NCT07092514
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Is NCT07092514 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Lenvatinib for thyroid cancer.
Treatment: Lenvatinib — This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: VEGF/VEGFR targeted therapy (sorafenib, pazopanib, vandetinib, axitinib, sunitinib, cabozantinib)
Exception: No more than 1 prior line for DTC
No more than 1 prior line of VEGF/VEGFR targeted therapy for DTC. Examples of VEGF/VEGFR therapies include sorafenib, pazopanib, vandetinib, axitinib, sunitinib, and cabozantinib, but others exist.
Cannot have received: VEGFR inhibitor (lenvatinib)
Prior treatment with lenvatinib [excluded].
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 100 K/cumm; Hemoglobin ≥ 9.0 g/dL
Kidney function
Creatinine clearance > 30 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN (5.0 x IULN in the presence of hepatic metastases)
Cardiac function
QTcF < 481 msec; NYHA class 2B or better required for patients with cardiac disease or history of cardiotoxic agents
Adequate bone marrow and organ function as defined below: Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 100 K/cumm; Hemoglobin ≥ 9.0 g/dL; Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN (5.0 x IULN in the presence of hepatic metastases); Creatinine clearance > 30 mL/min by Cockcroft-Gault; UPC ≤ 1000 mg/G; QTcF < 481 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07092514 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGF/VEGFR targeted therapy, VEGFR inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify